We have re-designed the anti-murine p75-Saporin targeted toxin (mu p75-SAP, Cat. #IT-16) and have produced a conjugate that is much more potent in our in vitro cell cytotoxicity assays. Previously, we used a rat monoclonal antibody. This antibody had been outperformed by our rabbit polyclonal AB-N01, in several assays, especially FACS analysis of murine p75-expressing […]
Targeting Tools: mu p75-SAP Improved Read More »
Contributed by Dr. James Smith, Wake Forest University School of Medicine, Department of Physiology and Pharmacology, Medical Center Blvd, Winston-Salem NC 27157 Recent data implicate cholinergic neurons in the brain processes that underlie reinforcement. The involvement of cholinergic neurons in cocaine self-administration has been recently demonstrated using muscarinic and nicotinic agonists and antagonists, microdialysis, assessment
Advanced Targeting Systems is pleased to announce the availability of polyclonal antibodies to somatostatin receptor (SSTr) sub-types 1 and 4. SSTr1 antiserum, Cat. #AB-N19 SSTr1 affinity-purified, Cat. #AB-N20AP SSTr4 affinity-purified, Cat. #AB-N21AP Antibody to SSTr1 SSTr1 is a 391 amino acid G-protein-coupled receptor that contains three glycosylation sites and that is expressed in several areas
Targeting Tools: Somatostatin Receptor Targeting Read More »
Contributed by ATS’s 2003 Society for Neuroscience Poster of the Year Award Winner:Dr. Jill McGaughy, Boston University, 64 Cummington St., Boston, MA 02215 Muscarinic cholinergic receptor activation in entorhinal cortex (EC) activates intrinsic depolarizing membrane currents, which cause self-sustained spiking activity in single neurons.[1] This effect may underlie delay activity and match-dependent activity changes in
Read the 2003 Newsletters and recent scientific references 2003, issue 1: Deep Lumbar Neurons Control Ejaculation / by Truitt W / featuring SSP-SAP, Cat. #IT-11 SFN Poster of the Year SP-SAP as a Chronic Pain Therapeutic: An Update Targeting Talk: Custom Peptide-Saporin Conjugates Targeting Tools: Dermorphin-SAP (Cat. #IT-12) 2003, issue 2: Biotinylated targeting: A viable
Targeting Trends 2003 Newsletter Read More »
Advanced Targeting Systems is pleased to announce the arrival of its newest second immunotoxin, Rat-ZAP (Cat. #IT-26). This new screening agent is constructed from goat anti-rat IgG conjugated to saporin. Like the other second immunotoxins, Hum-ZAP, Mab-ZAP and Rab-ZAP, it converts your primary antibody, in this case a rat IgG, into a potent cytotoxic agent
Targeting Tools: Rat-ZAP Read More »
Our thanks to Drs. Frank Porecca, Victory Hruby and Josephine Lai, Department of Pharmacology, The University of Arizona Health Sciences Center for sharing the results of their studies. Cholecystokinin (CCK) is widely distributed in the central nervous system and the gastrointestinal tract. The 33-amino acid peptide contains a carboxyl terminal octapeptide sequence Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2 which confers
Targeting Article: CCK-SAP in Binding Studies Read More »
Contributed by Dr. Patrick O. Kanold, Dept Neurobiology, Harvard Medical School, Boston, MA 02115.Dr. Kanold summarizes his work with ME20.4-SAP. A complete report was published in Science 301:521-525. The processing of information in the visual system happens in multiple stages. Retinal neurons in the eye connect to neurons in the lateral geniculate nucleus (LGN), that
Cover Article: Subplate Neurons and Functional Maturation of Thalamocortical Synapses Read More »
Advanced Targeting Systems announces the availability of two monoclonal antibodies to the dopamine transporter (DAT). These antibodies have become a standard for work on DAT and have already played a prominent role in the characterization of the dopamine transporter. The two antibodies are rat monoclonals, so they can be excellent for multiple staining protocols. Anti-DAT-NT, Cat.
Targeting Tools: Targeting the Dopamine Transporter Read More »
Dopaminergic neurons are widely studied because of their role in one of the devastating diseases of old age, Parkinson’s. Lesioning studies using 6-hydroxydopamine or MPTP have been useful in research on Parkinson’s Disease. However, these reagents have limitations such as MPTP affecting catecholaminergic neurons and 6-OHDA stability and specificity issues. Targeting dopaminergic neurons with an
Cover Article: A New Immunotoxin for Targeting Dopaminergic Neurons Read More »